Psoriasis epidemiology and demographics
|
Psoriasis Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Psoriasis epidemiology and demographics On the Web |
|
American Roentgen Ray Society Images of Psoriasis epidemiology and demographics |
|
Risk calculators and risk factors for Psoriasis epidemiology and demographics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Syed Hassan A. Kazmi BSc, MD [2]
Overview
The prevalence of psoriasis is estimated to be between 500 and 4,600 cases annually per 100,000 people. Psoriasis usually affects individuals of the Caucasian race. Psoriasis tends to primarily affect Northern European and Southeast Asian countries.
Epidemiology and Demographics
- Worldwide, the prevalence of psoriasis ranges from a low of 500 per 100,000 persons to a high of 4,600 per 100,000 persons.[1]
- The prevalence of psoriasis in the United States is 2,000 per 100,000 persons.[2]
- Worldwide, the prevalence of psoriatic arthritis (PsA) ranges from a low of 100 per 100,000 persons to a high of 1,000 per 100,000 persons.[3]
- Worldwide, 7,000 per 100,000 persons with arthritis are affected by psoriasis.[4]
Incidence
- Worldwide, the incidence of psoriasis ranges from a low of 78.9 per 100,000 persons (United States) to 230 per 100,000 persons (Italy).[5]
Age
- Psoriasis has two peaks with the mean age of first peak between 15 years to 25 years and mean of second peak occurring at 55 years to 60 years.[6]
Race
- Psoriasis tends to affect Caucasians more than other races with a prevalence of 2,500 per 100,000 Caucasian persons in the United States, which is higher than other ethnic populations in the country.[7]
Gender
- There is no gender predilection for psoriasis, although women are more severely affected once they develop the disease.[8]
Geographical distribution
- Psoriasis tends to affect Northern European and South East Asian countries.[9]
References
- ↑ Langley RG, Krueger GG, Griffiths CE (2005). "Psoriasis: epidemiology, clinical features, and quality of life". Ann. Rheum. Dis. 64 Suppl 2: ii18–23, discussion ii24–5. doi:10.1136/ard.2004.033217. PMC 1766861. PMID 15708928.
- ↑ Gladman DD, Antoni C, Mease P, Clegg DO, Nash P (2005). "Psoriatic arthritis: epidemiology, clinical features, course, and outcome". Ann. Rheum. Dis. 64 Suppl 2: ii14–7. doi:10.1136/ard.2004.032482. PMC 1766874. PMID 15708927.
- ↑ Gladman DD, Antoni C, Mease P, Clegg DO, Nash P (2005). "Psoriatic arthritis: epidemiology, clinical features, course, and outcome". Ann. Rheum. Dis. 64 Suppl 2: ii14–7. doi:10.1136/ard.2004.032482. PMC 1766874. PMID 15708927.
- ↑ Gladman DD, Antoni C, Mease P, Clegg DO, Nash P (2005). "Psoriatic arthritis: epidemiology, clinical features, course, and outcome". Ann. Rheum. Dis. 64 Suppl 2: ii14–7. doi:10.1136/ard.2004.032482. PMC 1766874. PMID 15708927.
- ↑ Parisi R, Symmons DP, Griffiths CE, Ashcroft DM (2013). "Global epidemiology of psoriasis: a systematic review of incidence and prevalence". J. Invest. Dermatol. 133 (2): 377–85. doi:10.1038/jid.2012.339. PMID 23014338.
- ↑ "Psoriasis: epidemiology, clinical features, and quality of life | Annals of the Rheumatic Diseases".
- ↑ Stern RS, Nijsten T, Feldman SR, Margolis DJ, Rolstad T (2004). "Psoriasis is common, carries a substantial burden even when not extensive, and is associated with widespread treatment dissatisfaction". J. Investig. Dermatol. Symp. Proc. 9 (2): 136–9. doi:10.1046/j.1087-0024.2003.09102.x. PMID 15083780.
- ↑ "Psoriasis - ScienceDirect".
- ↑ Danielsen K, Olsen AO, Wilsgaard T, Furberg AS (2013). "Is the prevalence of psoriasis increasing? A 30-year follow-up of a population-based cohort". Br. J. Dermatol. 168 (6): 1303–10. doi:10.1111/bjd.12230. PMID 23374051.